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Abacavir hypersensitivity reaction (ABC-HSR) is asso-
ciated with the presence of HLA-B*5701 allele. Alternative
tests for ABC-HSR associated allele determination are
needed where sequence-based HLA typing is not available,
particularly in resource-limited settings or developing
countries. This study focused on the development and
evaluation of two HLA-B*5701 tagging SNPs (single
nucleotide polymorphism) HCP5 (HLA complex P5)
rs2395029 and TNF (tumor necrosis factor) rs3093726
genotyping assays. Two hundred and thirteen purified
genomic DNA samples were used to evaluate the perfor-
mance characteristics of a HLA-B*5701 screening method
based on allele-specific polymerase chain reaction
(AS-PCR) with melting curve analysis. HCP5 rs2395029
and TNF rs3093726 were also genotyped using simple
probe real-time PCR assay. All samples were successfully
genotyped wherein AS-PCR genotyping provided 100%
sensitivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV) when compared with
specific HLA-B status by sequencing based assay. When
comparing the AS-PCR screening method with the HCP5
rs2395029 and TNF rs3093726 genotyping method, the
former had 100% sensitivity, 100% specificity, 100% PPV
and 100% NPV using a simple probe; while the latter one
had 95.24% sensitivity, 100% specificity, 100% PPV and
99.48% NPV, respectively. In conclusion, our study lends
support on a molecular tool for pharmacogenetic
screening in resource-limited settings. Thus, serious drug
hypersensitivity associated with ABC may potentially be
reduced in Thailand by further evaluation of the proposed
assay in clinical practice.
Authors’ details
1Ranathibodi Hospital Mahidol University, Thailand. 2Laboratory for
Pharmacogenomics, Faculty of Medicine Ramathibodi Hospital, Mahidol
University, Bang, Department of Pathology, Thailand.
Published: 18 July 2014
doi:10.1186/2045-7022-4-S3-P122
Cite this article as: Chonlaphat et al.: Evaluation of a pharmacogenetic
test in Thailand for abacavir hypersensitivity screening in human
immunodeficiency virus infection. Clinical and Translational Allergy 2014 4
(Suppl 3):P122.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit1Ranathibodi Hospital Mahidol University, Thailand
Full list of author information is available at the end of the article
Chonlaphat et al. Clinical and Translational Allergy 2014, 4(Suppl 3):P122
http://www.ctajournal.com/content/4/S3/P122
© 2014 Chonlaphat et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
